Insulin lispro Sanofi

  • Email
  • Help

Questions & Answers

On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Insulin lispro Sanofi, intended for the treatment of diabetes mellitus. The applicant for this medicinal product is Sanofi-Aventis groupe.

Insulin lispro Sanofi will be available as a solution for injection (100 units/ml). The active substance of Insulin lispro Sanofi is insulin lispro, a fast-acting insulin analogue (ATC code: A10AB04) which is absorbed more rapidly by the body and can therefore act faster than human insulin. The replacement insulin acts in the same way as naturally produced insulin; it works by facilitating uptake of glucose into skeletal muscle and fat tissue, and by inhibiting glucose output from the liver.

Insulin lispro Sanofi is a biosimilar medicinal product. It is highly similar to the reference product Humalog (insulin lispro), which was authorised in the EU on 30 April 1996. Data show that Insulin lispro Sanofi has comparable quality, safety and efficacy to Humalog.

The full indication is:

“For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Insulin lispro Sanofi is also indicated for the initial stabilisation of diabetes mellitus.”

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Name Language First published Last updated
CHMP summary of positive opinion for Insulin lispro Sanofi (English only) 2017-05-19  

Key facts

Product details for Insulin lispro Sanofi
NameInsulin lispro Sanofi
INN or common name

insulin lispro

Therapeutic area Diabetes Mellitus
Active substance

insulin lispro

Date opinion adopted18/05/2017
Company name

Sanofi-Aventis groupe

Application typeInitial authorisation

Related content